MIVAC Development is a biopharmaceutical company focused on discovery, development and commercialisation of novel treatments of autoimmune diseases, antiallergic therapies, treatments against Alzheimer’s Disease and mucosal vaccine development.

Company product portfolio:

• Therapeutic treatment of Rheumatoid Arthritis (RA) by inducing tolerance.
• Development of novel treatments against Alzheimer’s Disease (AD).
• Exploitation of the CTA1R7K-X-DD tolerance-inducing fusion protein for treatment of autoimmune diseases and allergies.
• New efficient and innovative vaccine against gastric ulcer and gastric cancer.

The company is continuously open to opportunities to expand its research portfolio by licensing new ideas within its research field. For inquiries, please see contact details.